At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 20 enrolled
Drug / intervention
T-DM1 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b Study Of Pembrolizumab In Combination With Trastuzumab-DM1 In Metastatic HER2-Positive Breast Cancer
In Brief
A Phase 1 clinical trial evaluating T-DM1 and Pembrolizumab for Breast Cancer. Completed, enrolled 20 participants across 2 sites.
Detailed Summary
This research study is studying a combination of drugs as a possible treatment for metastatic breast cancer. The interventions involved in this study are: * Pembrolizumab * Trastuzumab emtansine (also called T-DM1)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedJan 2017
Enrollment StartFeb 2017
Primary CompletionOct 2020
Study CompletionDec 2024
TodayJul 2026
First PostedJan 26, 2017
Enrollment StartFeb 17, 2017
Primary CompletionOct 29, 2020
Study CompletionDec 5, 2024
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 9.4 years ago
Interventions
T-DM1drug
-T-DM1 will be administered intravenousely in clinic on day 1 of each 3-week cycle
Pembrolizumabdrug
-Pembrolizumab will be administered intravenousely in clinic on day 1 of each 3-week cycle